Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Arcoxia by Year
Arcoxia (etoricoxib, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)
Merck Arcoxia: $0M in FY2020. No newer figure appears in the documents we track.
Latest, FY2020
0
Period ended Dec 31, 2020
Change on a year earlier
–
0 in FY2019
History
5 years
Since FY2016
Sources
3
Documents cited below
Where the FY2020 figure comes from
Source: Form 10-K (filed 2021-02-25) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcoxia (etoricoxib, legacy pre-Organon spin-off) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2021-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 0 | – | Form 10-K (filed 2020-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 0 | – | Form 10-K (filed 2019-02-27) ↗ |
Cite this data
StockData. (2026). Merck Arcoxia ($M), annual FY2016–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-arcoxia-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.